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Introduction {#sec1}
============

Persistent viral infections are often associated with the functional exhaustion of virus-specific CD8^+^ T cells ([@bib80]). Exhausted T cells have diminished effector functions and a distinct transcriptional profile relative to effector cells ([@bib84]). Receptor programmed death 1 (PD-1; also known as PDCD1) expression is upregulated on the surface of exhausted CD8^+^ T cells in mice infected by the lymphocytic choriomeningitis virus clone 13 strain (LCMV-Cl13) ([@bib7], [@bib19], [@bib25], [@bib67]). PD-1 is also upregulated during infection by the human immunodeficiency virus-1 (HIV-1) ([@bib19]) and hepatitis C virus ([@bib22]) and in monkeys infected with the simian immunodeficiency virus (SIV) ([@bib79]) and correlates with increased viral load ([@bib7], [@bib10], [@bib19], [@bib56]). Blocking antibodies against PD-1 restores CD8^+^ T cell functionality and viral clearance ([@bib25], [@bib28], [@bib67], [@bib84]). Checkpoint inhibitor blockade has also proven effective in the treatment of cancers such as melanoma ([@bib31], [@bib32]) and in combined therapy with anti-CTLA-4 ([@bib74], [@bib86]).

Two ligands, PD-L1 and PD-L2, have been identified for PD-1 ([@bib24], [@bib41], [@bib66], [@bib34]), and PD-1 has an immunoreceptor tyrosine-based switch motif (ITSM) that binds Src homology region 2 domain-containing phosphatases SHP-1 and SHP-2 ([@bib15], [@bib54]). The preponderance of studies are compatible with a negative function for the co-receptor ([@bib21], [@bib24], [@bib41], [@bib51], [@bib75]). Co-ligation can de-phosphorylate signaling proteins ([@bib15], [@bib57], [@bib90]) and form micro-clusters ([@bib90]). PD-1 can also upregulate inhibitory basic leucine zipper transcription factor, ATF-like BATF ([@bib59]), and induce motility paralysis ([@bib91]).

Despite this, the signal transduction pathway that regulates PD-1 transcription and expression in T cells has not been fully defined. Tyrosine kinases p56^lck^ and ZAP-70 activate T cells ([@bib61], [@bib82]). Src kinase p56^lck^ binds CD4 and CD8 ([@bib6], [@bib63], [@bib78]) and phosphorylates the TCR complex for ZAP-70 recruitment and phosphorylation of adaptors ([@bib6], [@bib13], [@bib14], [@bib61], [@bib64], [@bib82]). By contrast, the serine/threonine kinase, glycogen synthase kinase 3 (GSK-3), first characterized in phosphorylating glycogen synthase, is constitutively active in resting T cells ([@bib23], [@bib88]). Two isoforms of GSK-3 (α and β) have similar kinase domains but divergent N and C termini. They influence multiple signaling pathways although the two isoforms have distinct roles in cell survival ([@bib23]). In CD4^+^ T cells, GSK-3 facilitates the exit of nuclear factor of activated T cells (NFAT) from the nucleus ([@bib8], [@bib50]). TCR and CD28 phosphorylate and inactivate GSK-3 ([@bib53], [@bib87]), and constitutively active GSK-3β (GSK-3βA9) inhibits the proliferation of T cells ([@bib53]). GSK-3 in T cells operates independently of guanine nucleotide exchange factor VAV-1 ([@bib87]).

Although certain transcription factors have been implicated in *Pdcd1* transcription, the identity of the upstream signaling event(s) that control PD-1 expression has been unclear. Here, we have identified GSK-3α and GSK-3β (hereafter referred to as GSK-3 collectively) as a key kinase that upregulated *Tbx21* transcription for the downregulation of PD-1 and enhanced CD8^+^ cytolytic T cell function. We also demonstrated the use of small molecule inhibitors of GSK-3 to downregulate PD-1 for enhanced in vivo immunity involving the clearance of acute and chronic viral infections.

Results {#sec2}
=======

GSK-3 Downregulation or Inhibition Augments Cytolytic Killing of OT-I Transgenic T Cells {#sec2.1}
----------------------------------------------------------------------------------------

Although GSK-3 inhibits T cell expansion ([@bib5], [@bib53], [@bib87]), its role in the function of cytolytic T lymphocytes (CTLs) is not clear. To examine this, we initially examined CTL responses of T cells from OT-I transgenic mice that carry a MHC class I-restricted T cell receptor (TCR) specific for the SIINFEKL peptide of OVAlbumin (OVA~257-264~) as presented by H-2k^b^. T cells express the α and β isoforms of GSK-3 ([@bib17]). Small interfering RNAs (siRNAs) to the GSK-3α and β isoforms were used to knock down (KD) their expression in naive T cells by transfection prior to use in functional assays. siRNA treatment reduced GSK-3α and β protein substantially as seen by Western blotting ([Figure 1](#fig1){ref-type="fig"}A, iii), and by using fluorescent FITC-conjugated siRNAs, we found that more than 80% of cells had taken up the siRNAs ([Figure 1](#fig1){ref-type="fig"}A, iii). Further, siRNAs to GSK-3 increased OT-I-mediated cytolysis of mouse lymphoma cell line EL4-OVA targets significantly when compared to the control scrambled siRNA control ([Figure 1](#fig1){ref-type="fig"}A, i). There was a linear increase in killing of control samples expressing scrambled siRNAs across effector:target (E:T) ratios of 2:1 to 50:1 when assayed at day 5. This was confirmed by Scatchard plot analysis (r^2^ = 0.9603) ([Figure 1](#fig1){ref-type="fig"}A, iv). By contrast, the KD of GSK-3 increased the efficiency of CTL killing. The increase in killing efficiency seen was 3- to 5-fold for E:T ratios of 2:1 and 5:1. An E:T ratio of 2:1 showed the same efficiency of killing as seen at a ratio of 25:1 for control scrambled cells (i.e., p value = 0.333). A similar potentiating effect was also evident when assayed at days 4 and 7 (data not shown). These data showed that the KD of GSK-3 markedly increased the killing capacity of CD8^+^ OT-I cytolytic T cells.

ATP competitive and non-competitive inhibitors of GSK-3 kinase activity exist ([@bib18]). SB415286 competitively inhibits both isoforms with a preference of the β isoform ([@bib16]). Similar to the GSK-3 KD, inhibition of GSK-3 catalytic activity with SB415286 increased the killing efficiency of CTLs ([Figure 1](#fig1){ref-type="fig"}B, i). The linear increase ([Figure 1](#fig1){ref-type="fig"}B, iii) in the killing over E:T ratios was confirmed by Scatchard plot analysis (r^2^ = 0.9643). Incubation of OT-I T cells with SB415286 increased maximal killing by as much as 5-fold and shifted the killing curve by 10-fold (i.e., p value = 0.111). SB415286 also increased proliferation in response to OVA peptide to the same extent as when cells were cultured with anti-PD-1, as monitored by carboxyfluorescein succinimidyl ester (CFSE) labeling ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Cell counting with trypan blue exclusion showed that SB415286 increased slightly the cell number in response to anti-CD3 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and had no effect on cell viability ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These results showed that GSK-3 inactivation increases the killing efficiency of CD8-positive CTLs.

GSK-3 Downregulation or Inhibition Selectively Inhibits PD-1 Expression {#sec2.2}
-----------------------------------------------------------------------

We next assessed the effect of GSK-3 inhibition on receptor expression ([Figure 1](#fig1){ref-type="fig"}A, ii). GSK-3 siRNA reduced the frequency of cell surface expression PD-1 from 30% of cells to 7% of cells and also decreased the mean fluorescent intensity (MFI) of PD-1 expression without affecting CD28 or CTLA-4 expression. SB415286 reduced the frequency of cell expressing surface PD-1 expression on 54% to 7% of cells and decreased the MFI without affecting CTLA-4 or CD28 ([Figure 1](#fig1){ref-type="fig"}B, ii). Resting cells failed to express PD-1 or CTLA-4 ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The expression of CD44, CD62L, Tim3, CD3, BTLA, NKG2D, CD122, interleukin 2 receptor-alpha (IL-2Rα), CD25, CD69, Fas-ligand (FasL), CD8, and IL-2 was also unaffected by SB415286 ([Figure 1](#fig1){ref-type="fig"}C). Similarly, the expression of intracellular IL-2 and anti-apoptotic protein Bcl-2 was unaffected. However, consistent with enhanced CTL function, the frequency of cells expressing interferon-γ (IFN-γ), lysosomal-associated membrane protein 1 (Lamp1; CD107a), and cytotoxic T-lymphocyte-associated serine esterase 1 (Granzyme B; GZMB) was increased on OT-I CD8^+^ T cells.

siRNA selective for the GSK-3α isoform also reduced PD-1 expression while increasing OT-I killing ([Figure 1](#fig1){ref-type="fig"}D, iii and i). It reduced GSK-3α expression as confirmed by anti-GSK-3α blotting ([Figure 1](#fig1){ref-type="fig"}D, ii) and by flow cytometry ([Figure 1](#fig1){ref-type="fig"}D, iii) without affecting GSK-3β cell surface expression. siRNA GSK-3β was also tested but failed to show specificity and was not pursued (data not shown). These data showed that GSK-3α siRNA KD alone could downregulate PD-1 and increase the killing efficiency of CTLs.

Other structurally distinct inhibitors of GSK-3 decreased PD-1 expression and potentiated OT-I killing of targets ([Figure 1](#fig1){ref-type="fig"}E). These included ATP-competitive inhibitors SB216763, CHIR99021, and L803-mts, where SB216763 has a preference for the GSK-3α isoform and CHIR99021 and L803-mts preferentially inhibited GSK-3β ([@bib35]).

We next determined whether the reduction of PD-1 expression by GSK-3 inhibition was itself responsible for the enhanced CTL function by blocking with anti-PD-1 or PD L1-Fc (constant fragment) in the absence and presence of GSK-3 inactivation ([Figure 2](#fig2){ref-type="fig"}). PD-1 blockade increased the CTL killing efficiency to the same extent as GSK-3 siRNA as seen over multiple E:T ratios ([Figure 2](#fig2){ref-type="fig"}A). However, the addition of PD-1 or PD L1-Fc to GSK-3 siRNA-expressing cells did not increase killing beyond that seen with GSK-3 inactivation alone or vice versa. Identical results were obtained using anti-PD-1 or PDL1-Fc with SB415286 where blockade did not increase killing beyond that seen with the inhibitor, and vice versa ([Figure 2](#fig2){ref-type="fig"}B). Similar results were obtained using GSK-3 inhibitor SB216763 in combination with anti-PD-1 ([Figure S2](#mmc1){ref-type="supplementary-material"}).

siRNA KD of PD-1 expression in CD8^+^ T cells also increased cytolytic function ([Figure 2](#fig2){ref-type="fig"}D). PD-1 siRNA and SB415286 each reduced *pdcd1* transcription by \>85% reduction ([Figure 2](#fig2){ref-type="fig"}C) and enhanced CTL killing to the same degree. Further, combined siRNA and SB415286 increased CTL function no further than seen with either treatment alone. These observations confirmed that the modulatory effect of GSK-3 inactivation on OT-I CTL function was primarily due to PD-1 down-modulation.

GSK-3 Downregulation or Inhibition Blocks PD-1 Transcription {#sec2.3}
------------------------------------------------------------

We next confirmed that GSK-3 inactivation acted on *Pdcd1* transcription (encodes PD-1) in different contexts ([Figure 3](#fig3){ref-type="fig"}). Anti-CD3 ligation induces PD-1 expression on T cells ([@bib1]). Two-step real-time PCR was used to separate the reverse transcription reaction from the real-time PCR assay ([@bib81]). The presence of SB415286 was remarkably effective in blocking the induction of *Pdcd1* transcription by anti-CD3 over 72 hr ([Figure 3](#fig3){ref-type="fig"}A). GSK-3 siRNA also inhibited *Pdcd1* transcription in OT-I T cells in response to EL-4-OVA cells ([Figure 3](#fig3){ref-type="fig"}B). In addition, SB415286 blocked *Pdcd1* transcription in OT-I responses to EL4-OVA ([Figure 3](#fig3){ref-type="fig"}C). A titration of structurally distinct inhibitors such as CT99021, AR-AO14418, and TZD8 also inhibited *Pdcd1* transcription, whereas the phosphatase inhibitor NSC 87877 had no effect (data not shown).

Conversely, we found that SB415286 increased the transcription of *Tbx21* (encodes T-box transcription factor T-bet) concurrent with *Pdcd1* inhibition. This was observed in response to anti-CD3 ligation without affecting Tcf7-mediated transcription ([Figure 3](#fig3){ref-type="fig"}A). Similarly, GSK-3 siRNA in OT-I T cells increased *Tbx21* transcription in response to EL4-OVA ([Figure 3](#fig3){ref-type="fig"}B) as did incubation with SB415286 for 5 and 6 days ([Figure 3](#fig3){ref-type="fig"}C). Chromatin immunoprecipitation (ChIP) with two different anti-T-bet antibodies followed by PCR confirmed that GSK-3 inhibition increased T-bet binding to *Pdcd1* in anti-CD3-activated primary or Jurkat T cells ([Figure 3](#fig3){ref-type="fig"}D). Further, anti-CD3 activation of cells expressing the *Ifng CNS-12* promoter construct driven by T-bet ([@bib36]) and incubated with SB415286 showed that increased transcription ([Figure 3](#fig3){ref-type="fig"}E). These data confirm that GSK-3 inactivation acted to increase *Tbx21* transcription and its binding to the PD-1 promoter.

We next examined whether GSK-3 mediated its effect on *Pdcd1* transcription via T-bet ([Figure 3](#fig3){ref-type="fig"}F and 3G). T-bet siRNA expression decreased the presence of T-bet transcripts while increasing PD-1 transcription consistent with its negative regulation of PD-1 ([@bib37]). At the same time, SB415286 failed to reduce PD-1 expression in cells expressing T-bet siRNA, as assessed by flow cytometry. Similar findings were observed using OT-I CTL killing as a read-out ([Figure 3](#fig3){ref-type="fig"}G). T-bet siRNA impaired CTL killing over different E:T ratios as well as reducing GZMB and Lamp1 expression ([Figure 3](#fig3){ref-type="fig"}G). This inhibition was completely reversed by PD-1 blockade showing that the T-bet inhibition of CTL OT-I responses was due primarily to increased PD-1 expression. By contrast, SB415286 failed to reverse the inhibition of killing by T-bet siRNA. This result indicated that the modulatory effects of GSK-3 on PD-1 expression operated in a pathway that required the expression of T-bet.

As an additional control, we also re-expressed PD-1 in SB415286-exposed OT-I T cells and assessed whether this could reverse the enhancement of CTL killing ([Figure 3](#fig3){ref-type="fig"}H). EL-4-OVA-activated SB415286-treated cells were transfected on day 5 of culture with PD-1 followed by an assessment of cytolysis 48 hr later. The SR alpha promoter plasmid with PD-1 (pPD1) induced PD-1 expression similar to levels on activated T cells. This expression reversed the enhanced killing induced by SB415286, confirming that PD-1 downregulation was responsible for the potentiating effects of GSK-3 inactivation on CTL function.

Another possible connection to GSK-3 was the transcription factor NFATc1 because GSK-3 inhibition increases nuclear NFATc1 in CD4^+^ T cells ([@bib8], [@bib50]). *Pdcd1* expression is regulated by NFAT2 ([@bib52]) and NFAT binding sites exist in*Tbx21* ([@bib45]). NFATc1 siRNA downregulated *nfat* transcripts ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, unlike GSK-3 inhibition, NFATc1 siRNA inhibited all events including T-bet ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and PD-1 ([Figure S3](#mmc1){ref-type="supplementary-material"}C) transcription and CTL killing ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Cyclosporin A (CsA) treatment also inhibited *Tbx21*, *Pdcd1*, and CTL killing and SB415286 was unable to rescue the inhibitory effect ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D).

In Vivo GSK-3 Inhibition Decreases PD-1 Expression and Enhances CTL Function of CD8^+^ OT-I T Cells {#sec2.4}
---------------------------------------------------------------------------------------------------

To assess the in vivo effect of GSK-3 inactivation on PD-1 expression, we initially examined the in vivo generation of OT-I responses to OVA peptide in the presence of SB415286. OVA peptide was injected intravenously (i.v.) into OT-I transgenic mice with and without SB415286 followed by the harvest of spleens and lymph nodes (LNs) at day 7 ([Figure 4](#fig4){ref-type="fig"}A) or a repeat injection of the drug at day 7 followed by a harvest on day 14 ([Figure 4](#fig4){ref-type="fig"}B). T cells from extracted spleens/LNs were then assessed for the ex vivo killing of EL4-OVA targets. From this, the in vivo injection with SB415286 resulted in a 2- to 5-fold increased killing efficiency of ex vivo extracted CTLs over a range of E:T ratios. qPCR of extracted T cells also confirmed that in vivo exposure to SB415286 inhibited *Pdcd1* transcription. These data provided initial evidence that the in vivo inhibition of GSK-3 with a small molecular inhibitor suppressed PD-1 expression for enhanced CTL function.

GSK-3 Regulates Clearance of Herpes MHV-68 Virus Infection via PD-1 Downregulation {#sec2.5}
----------------------------------------------------------------------------------

We were next interested in whether small molecule inhibitors of GSK-3 could treat viral infections via downregulation of PD-1. To test this, we infected BALB/c mice intra-nasally with the luciferase^+^ Murid herpesvirus 68 (MHV-68), an isolate of Murid herpesvirus 4 (MuHV-4) ([@bib72]), in the presence or absence of SB415286. Viral luciferase expression effectively tracks the spread of infection as monitored by luciferin injection and CCD camera scanning ([@bib49]). The presence of virus was followed over time from the nose to lung alveoli where lytic replication occurs. In the MHV-68 model, day 7 corresponds to the latent period and day 14 to chronic infection ([@bib72]). We found that SB415286 markedly reduced the luciferase signal in the nose and lungs in mice as assessed on day 7 ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}B). Quantitative comparisons of maximum radiance confirmed an increase in the presence of luciferase^+^ MHV-68 in lungs from day 3 to 7, which drug treatment reduced from 10^6-7^ to 10^4-5\ ps-1^. The viral load (plaque forming units \[pfu\]) was also significantly reduced from 6 × 10^4^ to 1 × 10^4^ at day 7 and from 2 × 10^4^ to 4 × 10^3^ at days 7 and 14 ([Figure 5](#fig5){ref-type="fig"}B). Quantitative real-time PCR of T cells extracted from spleens of SB415286-treated mice showed a reduction in *pdcd1* transcription concurrent with an increase in T-bet expression ([Figure 5](#fig5){ref-type="fig"}C). Moreover, splenic T cells from mice treated with SB415286 and tested ex vivo for the killing of targets pulsed with MHV-68-derived peptide M2~91--99~ showed an increase in killing capacity ([Figure 5](#fig5){ref-type="fig"}D).

To assess whether the GSK-3 modulation of PD-1 expression was responsible for this effect, we next conducted the same experiment using a combination of anti-PD-1 blockade with SB415286 ([Figure 5](#fig5){ref-type="fig"}E). Anti-PD-1 blockade reduced viral spread as seen by the reduction in max radiance (i.e., from 4 × 10^7^ to 8 × 10^5\ ps-1^) when assessed on days 3, 5, and 7. SB415286 reduced the maximum radiance to the same degree, and importantly, when used in combination, anti-PD-1 blockade had no further effect than SB415286, and vice versa. Measurement of viral titers at days 7 and 14 showed that anti-PD-1 blockade and SB415286 reduced viral titers to the same extent ([Figure 5](#fig5){ref-type="fig"}F). Further, the injection of anti-PD-1 did not increase the response further in mice injected with SB415286 and vice versa. These observations showed that the effect of GSK-3 inhibition in vivo in response to MHV-68 was mediated via PD-1 downregulation.

Lastly, the increase in viral clearance due to GSK-3 inhibition was accompanied by an increase in Lamp1 (i.e., from 120 to 210 GeoMFI, p \< 0.001), GZMB (i.e., from 11 to 14GeoMFI, p \< 0.001), and IFN-γ (i.e., from 29 to 43 GeoMFI, p \< 0.05) expression ([Figure 5](#fig5){ref-type="fig"}G). By contrast, the presence of SB415286 did not alter the frequency of cells expressing CD44 and CD62L ([Figure 5](#fig5){ref-type="fig"}H), in accord with studies on *Pdcd1*^−/−^ T cells ([@bib38]). Cells expressing CD4 also did not change. By contrast, M2~91--99~ tetramer staining showed increased numbers of M2 peptide-specific CD8^+^ T cells ([Figure 5](#fig5){ref-type="fig"}I). Overall, our findings show that the in vivo inactivation of GSK-3 can significantly reduce the progression of MHV-68 infection in mice due to reduced PD-1 expression.

GSK-3 Augments Clearance of Chronic LCMV-Cl13 Infection {#sec2.6}
-------------------------------------------------------

Exhausted virus-specific CD8^+^ T cells during chronic infection are characterized by prolonged expression of PD-1 in response to the lymphocytic choriomeningitis virus variant LCMV-Cl13 ([@bib3], [@bib7], [@bib19]). This contrasted with the LCMV Armstrong strain (LCMV-Arm) that induces a more robust response and resolves within 8--10 days. To assess the role of the GSK-3-T-bet-PD-1 pathway in LCMV-Cl13 infection, mice were infected i.v. with the LCMV-Cl13 variant followed by an injection with SB415286 at day 25 when exhaustion had been established in the chronic phase of the infection ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Mice were then monitored on days 23, 25, 30, and 37. DbGP~33-41~ peptide staining of CD8^+^ T cells from mice infected with LCMV-Cl13 demonstrated high expression of PD-1, unlike T cells from LCMV-Arm-infected mice. Further, D^b^GP~33-41~^+^CD8^+^ T cells from mice treated with SB415286 showed a significant reduction in global PD-1 expression relative to untreated mice, when assayed on days 25 and 30 ([Figure 6](#fig6){ref-type="fig"}A). PD-1 expression was inversely related with an increase in T-bet expression (r^2^ = 0.7) ([Figure 6](#fig6){ref-type="fig"}B). Consistent with PD-1 downregulation, SB415286-treated mice had a significant reduction in viral load in blood at days 30 and 37 ([Figure 6](#fig6){ref-type="fig"}C). When expressed as percent infectivity compared to day 23 ([Figure 6](#fig6){ref-type="fig"}D), mice showed a range of responses with more than a log reduction between some untreated and treated mice (i.e., 10^2^ from control mice to 5 × 10^−2^), as reported in response to anti-PD-1 ([@bib12], [@bib28], [@bib83]). This was accompanied by a slight increase in the number of GP~33-41~^+^CD8^+^ T cells ([Figure 6](#fig6){ref-type="fig"}E). By contrast, SB415286 treatment had no obvious effect on cell number ([Figure 6](#fig6){ref-type="fig"}F) or PD-1 expression ([Figure 6](#fig6){ref-type="fig"}G) of CD4^+^ T cells (CD11a^+^CD49d^+^CD4^+^) from mice infected with LCMV-Cl13. LCMV-specific CD4^+^ T cells express CD11a^hi^CD49d^+^ ([@bib48]).

Further, GP~33-41~^+^CD8^+^ T cells showed a significant increase in the percentage of cells expressing IFN-γ and tumor necrosis factor-alpha (TNF-α) at days 30 and 37 induced by SB415286 ([Figure 6](#fig6){ref-type="fig"}H). As a positive control, the Armstrong strain of the virus also showed increased numbers of cells expressing IFN-γ and TNF-α. These data showed that the inhibition of the GSK-3 pathway can also modulate PD-1 expression during LCMV-Cl13 chronic infection that is associated with T cell exhaustion.

Discussion {#sec3}
==========

Despite the importance of PD-1 in modulating T cell responses, the upstream pathway responsible for PD-1 downregulation expression has yet to be defined. Here, we have identified GSK-3 as a key upstream kinase that regulated PD-1 expression and enhanced CD8^+^ CTL function for the in vivo clearance of MHV-68 and LCMV-Cl13 viral infections. GSK-3 inactivation operated in a pathway that increased *Tbx21* transcription that in turn inhibited *Pdcd1* transcription and expression for enhanced CD8^+^ CTL killing efficiency. We also demonstrated the use of small molecular inhibitors of GSK-3 to reduce PD-1 expression for enhanced in vivo immunity.

Previous studies have shown that GSK-3β inhibits the proliferation and development of CD4^+^ T cells ([@bib9], [@bib53], [@bib65], [@bib87]). Our findings provided an additional mechanism to account for inhibition where inactivation of GSK-3α/β downregulates PD-1, thereby removing the inhibitory effect of the co-receptor on proliferation. Its downregulation by siRNA, or chemical inhibition, potently inhibited PD-1 transcription in CD8^+^ T cells resulting in an enhancement of OT-I killing of targets by 5- to 10-fold. In a screen of receptors, only the expression of PD-1 on CD8^+^ T cells was inhibited. PD-1 blockade, either in vitro or in vivo, did not increase the enhanced killing efficiency of CTLs induced by GSK-3 inactivation, or vice versa. If GSK-3 operated primarily via a different pathway, additional effects of GSK-3 inhibition beyond PD-1 blockade would have been expected. Further, the ectopic PD-1 expression completely reversed the enhancement of killing efficiency induced by GSK-3 inhibition. Although GSK-3 can regulate the expression of numerous other genes, our findings underscored the dominance of GSK-3's effect on PD-1 on CD8^+^ CTL function. In accord, PD-1 has previously been shown to inhibit the generation of cytolytic T cells ([@bib55]). A range of structurally distinct competitive and non-competitive inhibitors inhibited PD-1 transcription, whereas the phosphatase inhibitor NSC 87877 had no effect (data not shown).

Our findings also demonstrated the in vivo application of small molecule inhibitors of GSK-3 for the downregulation of PD-1 in immune therapy. Injection of SB415286 and other inhibitors enhanced OT-I CTL in vivo responses, as well as the clearance of acute or chronic infection by MHV-68 and LCMV-Cl13. GSK-3 inhibition reduced PD-1 expression and LCMV-Cl13 viral titer by a half log when administered during the exhaustion phase of infection. As with anti-PD-1 blockade, a range of effect was seen among individual mice with as much as a log reduction in infection between control and SB415286-treated mice. These effects were similar to those reported with VV/GP33 ([@bib28]) and in anti-PD1-treated mice (i.e., a half log difference) ([@bib12]) as well as in *Tbx21*^*−/−*^ mice ([@bib37]). GSK-3 inhibition also restored the functionality of exhausted GP~33-41~^+^CD8^+^ T cells as evidenced by the increased expression of TNF-α and IFN-γ. The connection to IFN-γ is intriguing given reports of an impairment of IFN-γ in patients carrying certain PD-1 polymorphisms ([@bib40]). Our findings suggest that GSK-3 inhibitors could be used to substitute or complement anti-PD-1 or PD-L1 therapy presently in use in infection and cancer ([@bib7], [@bib19], [@bib25], [@bib27], [@bib28], [@bib86]) or in combination with CTLA-4 blockade ([@bib74], [@bib86]).

Mechanistically, we found that GSK-3 inhibition operated by increasing the transcription of T-bet, a central regulator of Th1 cell differentiation ([@bib26]). Surprisingly, this connection between GSK-3 and T-bet had not previously been reported and could have a range of functional implications to T cell differentiation and function. In CD8^+^ T cells, GSK-3 inactivation increased Tbx21 transcription for enhanced T-bet expression that in turn inhibited *Pdcd1* transcription. We showed by ChIP analysis that GSK-3 inactivation increased T-bet binding to the *Pdcd1* promoter and confirmed with siRNAs that T-bet negatively regulates *Pdcd1* transcription ([@bib37], [@bib85]). Importantly, we found that GSK-3 downregulation of PD-1 was dependent upon T-bet expression as shown by the inability of SB415286 to downregulate PD-1 on T-bet siRNA-expressing cells. In our model, GSK-3 acts as a suppressor of a suppressor of a suppressor, namely PD-1. Upon activation, GSK-3 is inhibited by TCR/CD28-induced phosphorylation leading to increased T-bet expression and the development of effector function. In the case of CD28, GSK-3 inactivation involves its binding and activation of phosphatidyl-inositol 3 kinase (PI3K) and protein kinase B (AKT) ([@bib58], [@bib62]). However, the inactivation process is inefficient, allowing the induction of some PD-1 expression via the general activation of T cells. The application of drug or interfering RNAs allowed for a more complete inactivation of GSK-3 and reduced PD-1 expression. Remarkably, we also noted that PD-1 blockade reversed T-bet siRNA inhibition of OT-I CD8^+^ CTL responses, indicating that altered PD-1 expression can account for much of the T-bet regulation of CTL function.

It also appeared that T-bet did not affect the transcription of all its potential promoters in CD8^+^ T cells. For example, although T-bet binds to the Tim3 promoter ([@bib4]), we saw no consistent effect of GSK-3 inhibition on Tim3 expression. This could be related to chromosomal accessibility or other factors affected by GSK-3 signaling. However, despite the dominance of PD-1 in CD8^+^ T cells, GSK-3 could potentially still directly affect other genes that might alter CTL function in other conditions such as cancer. For example, T-bet binding sites exist in the GZMB and IFN-γ promoters ([@bib45]). In other words, an increase in GZMB and IFN-γ is due to PD-1 downregulation with an additional contribution direct GSK-3 upregulation of GZMB and IFN-γ gene expression. We did not observe an effect on CD44 or CD62L expression, agreeing with reports of normal CD44/CD62L expression on *pdcd1*^*−/−*^ T cells ([@bib38]).

The connection of GSK-3-T-bet-PD-1 axis to other signaling events is also possible. The transcription factor FoxO1 sustains expression of PD-1 during chronic LCMV-Cl13 infection involving increased PKB/AKT activity ([@bib71]). Notch positively regulates PD-1 transcription ([@bib47]), whereas activator protein 1 (AP1) and Blimp1 (B-lymphocyte maturation protein 1) suppresses it ([@bib43], [@bib89]). By contrast, although cytokine receptors increase PD-1 expression via STATs (Signal transducers and activators of transcription) ([@bib39]), these do not obviously intersect with antigen-receptor signaling in T cells.

In CD4^+^ T cells, GSK-3 inhibition increases the residency of nuclear NFATc1 ([@bib8], [@bib50]), whereas *Pdcd1* expression is regulated by NFAT2 ([@bib52]). Whether this pathway is connected to GSK-3 regulation of PD-1 in effector CD8^+^ T cells is unclear because we failed to observe an effect of GSK-3 inactivation on PD-1 expression on CD4^+^ T cells during LCMV-Cl13 infection. Whether this lack of an effect will be seen in other in vivo contexts needs to be clarified. The situation is also complicated by the fact that NFATc1 regulates many events ([@bib44], [@bib46]). In our hands, NFATc1 inactivation inhibited T-bet, PD-1 transcription, and CTL killing; this contrasts with GSK-3 inactivation in CD8^+^ T cells, where PD-1 transcription was inhibited but T-bet transcription and CTL function were increased. An NFAT1 mutant unable to bind to AP-1 promotes CD8^+^ T cell exhaustion ([@bib45]). NFAT2 has been reported to be primarily nuclear in tolerant CD8^+^ T cells ([@bib70]), although others have reported that NFAT2 is not nuclear in exhausted T cells ([@bib2]). We previously found a connection between NFATc1 and adaptors ADAP and SKAP1 in PD-1 expression indirectly due to suboptimal conjugation and activation of T cells ([@bib42]). These different findings underscore a complexity of NFAT in interfacing with different activation events in T cells. Overall, the full therapeutic potential of GSK-3 inhibitors in the downregulation of PD-1 in the treatment of infection and cancer remains to be clarified.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

C57BL/6 and BALB/c (Harlan UK) mice were housed at the Central Biological Services (Cambridge University). Mice were infected when 6--8 weeks old under the Home Office Project License 80/2189. Antibodies and GSK-3 inhibitors are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

In Vitro Assays {#sec4.2}
---------------

Primary mouse T cells (OT-I, C57/b6) were isolated from spleens and cultured in vitro in supplemented RPMI 1640 ([@bib60], [@bib77]). T cell enrichment was performed with T cell purification columns (R&D Systems). OVA-specific CD8^+^ cytolytic T cells were generated by incubating OT-I splenocytes with SIINFEKL peptide of OVA (OVA~257-264~) at 10 ng/mL for 5--7 days, usually in experiments using SB415286 such as in [Figure 1](#fig1){ref-type="fig"}B. Alternatively, EL-4 cells were incubated with 10 nM OVA~257-264~ peptide (Bachem) for 1 hr at 37°C and treated with mytomycin C (Sigma-Aldrich) (final concentration of 10 μg/mL) prior to mixing with primary T cells by co-culturing at a ratio of 1:5 of EL4 and T cells in order to generate cytotoxic T cells.

CTLs were generated in the presence or absence of inhibitors and/or anti-PD-1 or anti-PDL-1 blockade for 5--7 days prior to washing and analysis by FACs or PCR or in cytoxicity assays. In some cases, naive OT-I T cells were first incubated with OVA peptide with or without GSK-3 inhibitors and/or anti-PD-1 or PD-L1-Fc (1--3 μg/mL). 25 mM stock solutions were prepared in DMSO and diluted to a concentration of 1--10 μM in vitro. NSC 87877 was used at 50 μM (T*ocris* Bioscience *Boston* Biochem) ([@bib69]) and cyclosporin A (CsA) (Sigma) at 0.5 μg/mL.

In certain cases, naive cells were subjected to nuclear transfection in the presence of various siRNA oligos (i.e., GSK-3). 3.0--5.0 μg of siRNAs were added to 1 × 10^6^ T cells and suspended in 100 μL of nucleofector solution for T cells (Amaxa Biosystems). Cells were electroporated with a Nucleofector (Amaxa Biosystems), as previously described ([@bib68], [@bib76]). In certain instances, pre-activated T cells were transfected with mouse PD-1 ([@bib73]).

For in vitro cytotoxic assays, transfected T cells were plated in 96-well plates at the start of culture with activating EL4 cells pulsed with OVA peptide except in the case of the MHV-68 in which EL4s were pulsed with the M2 peptide (M2~91--99~, GFNKLRSTL) (SIGMA-Genosys) ([@bib33]). Cytotoxicity was assayed with a Cytotox 96 nonradioactive kit (Promega) according to the instructions provided.

Luciferase reporter assays were performed with Dual-luciferase Reporter Assay System (Promega).

Quantitative Real-Time PCR and Chromatin Immunoprecipitation {#sec4.3}
------------------------------------------------------------

Single-strand cDNA was synthesized with an RT-PCR kit (QIAGEN) and phases of PCR amplification were monitored to ensure a measurement of real-time transcription ([@bib81]). ChIP (Pierce Agarose ChIP kit) was conducted according to the manufacturer's protocols (Thermo Scientific \#26156).

Viruses and In Vivo Luciferase Imaging {#sec4.4}
--------------------------------------

Luciferase tagged-MHV-68 viral stock isolation, infection, and imaging were conducted as described ([@bib20]) and in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Mice received treatment on days 0, 3, 5, 7, and 10 of either PBS, SB415286 (10 μg/kg), or anti-PD1/PD-L1 (100 μg per dose/mouse) intraperitoneally (i.p.). For luciferase imaging, mice were injected i.p. with luciferin (2 μg per mouse), anesthetized with isoflurane, and scanned with an IVIS Lumina (Caliper Life Sciences) as previously described ([@bib49]). For LCMV, LCMV-Arm and LCMV-Cl13 strains were prepared as described ([@bib29], [@bib30]). Mice were infected i.v. with 2 × 10^6^ pfu of LCMV-Arm or LCMV-Cl13. Mice received doses of SB415286 or PBS every 48 hr from day 23 until day 37. LCMV titers in the serum were determined by vero cell plaque assays as described previously. Viruses were also grown, identified, and quantified as described ([@bib3], [@bib11]).

In Vivo Priming OT-I Tg Cells {#sec4.5}
-----------------------------

OVA peptide (1 μg) was injected i.v. into OT-I Tg mice with and without SB415286 (10 μg) on days 0 and 7. T cells were purified from spleens harvested on days 7 and 14.
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![GSK-3 Inactivation via siRNA KD or Small Molecule Inhibitors Specifically Downregulated PD-1 Expression with Enhanced CTL Function\
(A) i: siRNA against GSK3 increases the cytolytic killing of OT-I CD8^+^ T cells. Scrambled siRNA (gray bars), siRNA against GSK3 (blue bars) (n = 5). ii: Flow cytometry profiles of receptor expression (gray line, isotype control; green line, scrambled siRNA; red line, GSK3 siRNA). iii: Anti-GSK3 blotting of cell lysates; FITC-tagged siRNA uptake. iv: Scatchard plot analysis.\
(B) i: OT-I T cells were incubated without (gray bars) or with SB415286 (blue bars) (n = 5). ii: Flow cytometry profiles (as above except red line: SB415286). iii: Scatchard plot analysis.\
(C) Flow cytometry profiles. Gray line, isotype control; green line, untreated cells; red line, cells incubated with SB415286.\
(D) i: Cytolytic assay using GSK-3α siRNA, scrambled control siRNA (gray bars), or siRNA against GSK3α (blue bars) (n = 5). ii: GSK-3α-specific blot. iii: Flow cytometry profiles of GSK-3α, GSK-3β, and PD-1.\
(E) i: Cytolytic assays using other GSK-3 inhibitors. ii: Flow cytometry profiles of PD-1 in the presence or absence of the specific inhibitor (gray line, isotype control; green line, scrambled siRNA; red line, inhibitor).\
Error bars based on triplicate values in individual experiments; data shown representative of five independent experiments.](gr1){#fig1}

![GSK-3 Potentiates OT-I Cytolytic Killing of EL4-OVA Target Cells via the Downregulation of PD-1\
(A) Percent target killing of EL4-OVA targets by OT-I CD8^+^ CTLs expressing scrambled or GSK-3 siRNA in the presence or absence of blocking anti-PD-1 or PDL1-Fc.\
(B) Percent killing of EL4-OVA targets by OT-I CD8^+^ CTLs incubated in the presence or absence of SB415286 with or without blocking anti-PD-1 or PDL1-Fc. OVA alone: light gray bars; anti-PD-1: dark blue bars; PD-L1-Fc: light blue bars (n = 4).\
(C) Relative *Pdcd1* expression in the presence and absence of PD-1 siRNA and/or SB415286.\
(D) Percent target killing from conditions in (C).\
Error bars based on triplicate values in individual experiments; data shown representative of ≥4 independent experiments.](gr2){#fig2}

![GSK-3 KD or Drug Inactivation Inhibits PD-1 and Increases *Tbx21* Transcription and Binding to the *Pdcd1*\
(A--C) *Tbx21* and *Pdcd1* transcription in response to anti-CD3 activation with or without SB415286 (A) (n = 4), siRNA GSK-3α/β KD in OT-I cells in response to OVA (B) (n = 3), and in OT-I T cells responding to OVA peptide with and without SB415286 (C) (n = 3).\
(D) ChIP using anti-T-bet antibodies 2-H10 and 4B10 followed by PCR analysis of *Pdcd1* promoter. Mouse T cells (left); Jurkat T cells (right).\
(E) *Tbx21*-driven *Ifng CNS-12* promoter activity in response to CD3 with or without SB415286.\
(F) Effect of T-bet siRNA on *Pdcd1* and *Tbx21* transcription (top). Flow cytometry of PD-1 expression on T cells expressing scambled siRNA or T-bet siRNA in the presence or absence of SB415286 (bottom).\
(G) CTL killing efficiency of T-bet siRNA-expressing CTLs in the presence of anti-PD-L1 blockade and/or SB415286 and on expression of GZMB and Lamp1 expression in T-bet siRNA-expressing OT-I cells (n = 3).\
(H) Killing efficiency of OT-I CTLs exposed to SB415286 followed by pPD-1 expression and flow cytometric profile of restored PD-1 expression (n = 3).\
Error bars based on triplicate values in individual experiments; data shown representative of ≥3 independent experiments.](gr3){#fig3}

![GSK-3 Inactivation In Vivo Suppresses PD-1 and Increases T-bet Expression Concurrent with Enhanced OT-I CTL Function\
SB415286 administered in vivo on days 0 or 7 and cells purified ex vivo on days 7 or 14. Ex vivo purified T cells were then assessed for cytolytic activity (percent target killing) and qPCR for *Pdcd1* expression on days 7 (A) and 14 (B). Mean and SD of six mice per group.](gr4){#fig4}

![In Vivo GSK-3 Inhibition Increased Acute MHV-68 Viral Clearance via PD-1 Downregulation\
BALB/c mice were intra-nasally infected with MHV-68 with/without an i.p. injection of SB415286.\
(A) Histogram showing maximal radiance values on days 3, 5, and 7 (n = 20).\
(B) Histogram showing viral titers at days 7 and 14 (n = 5).\
(C) qPCR values of *Pdcd1* and *Tbx21*. Gray bars, non-treated; blue bars, SB415286 treated. Each column represents a different mouse.\
(D) CTL killing of EL4-M2 cells (percent target killing). T cells isolated from spleen were assessed for ex vivo killing of EL4-M2 cells (n = 3).\
(E and F) BALB/c mice were infected with MHV-68 and treated with anti-PD1 with and without SB415286 undergoing the same regime as in (A) (n = 3). Radiance values on days 3, 5, and 7 (E); viral titers on days 7 and 14 (F).\
(G) Flow cytometry profile of Lamp1, GZMB, and IFN-γ expression (n = 3).\
(H) Flow cytometry profiles of CD44, CD62L, and CD4 expression. Gray line, isotype control; green line, T cells stimulated with OVA peptide alone; red line, T cells stimulated with OVA peptide in the presence of SB415286.\
(I) Absolute numbers of M2 peptide-specific CD8^+^ T cells.\
Mean and SD of at least five mice per group. Also see [Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B.](gr5){#fig5}

![GSK-3 Inhibition In Vivo Can Enhance Viral Clearance in Chronic Infection by LCMV-Cl13\
Mice were infected i.v. with LCMV-Cl13 and treated with/without SB415286.\
(A) Flow cytometry depicting PD-1 expression on D^b^GP~33-41~ CD8^+^ T cells in LCMV-Cl13-infected mice treated with and without SB415286. Right plot represents MFI values for PD-1 expression D^b^GP~33-41~ CD8^+^ T cells at 23--40 days after infection (n = 2). Blue box, DMSO-treated LCMV-Cl13-infected mice; red box, SB415286-treated LCMV-Cl13-infected mice; white box, LCMV-Arm control.\
(B) Inverse relationship between PD-1 and T-bet in mice treated with SB415286 (boxes as in A; each box represents a different mouse).\
(C) Viral load in serum of LCMV-Cl13-infected mice treated with or without SB415286. pfu/ml viral titers in serum (×10^5^) days 23, 30, and 37.\
(D) Percent infectivity at days 30 and 37 compared to day 23.\
(E) Number of D^b^GP~33-41~ CD8 T cells taken from the spleens of mice, treated with or without SB415286 over 30--40 days.\
(F and G) Number of CD4^+^ T cells (CD11a^+^CD49d^+^CD4^+^) (F) and total number of CD4^+^ cells (G) from mice infected with LCMV-Cl13 and treated with or without SB415286.\
(H) Flow cytometry profiles of IFN-γ- and TNF-α-expressing T cells from mice infected with LCMV-Arm control (day 37) or LCMV-Cl13 (day 25, 30, 37). Histograms (linear scale and log scale) showing the numbers of D^b^GP~33-41~ CD8^+^ T cells expressing IFN-γ and TNF-α after GP~33-41~ peptide stimulation of PBMCs ex vivo from untreated and SB415286-treated mice. Blue boxes, DMSO-treated mice; red boxes, SB415286 treated; white boxes, LCMV-Arm control. Each box represents a different mouse. Data represent two combined independent experiments of n ≥ 4 mice per group.\
Statistics for (B) were done by 2-way ANOVA, (C) and (E) by non-parametric Mann-Whitney at each time point. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr6){#fig6}
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